If a CT shows a liver lesion that is indeterminate, which imaging modality is commonly recommended for further characterization?

If a CT shows a liver lesion that is indeterminate, which imaging modality is commonly recommended for further characterization?

• A. Ultrasound.
• B. MRI.
• C. PET-CT.
• D. CT without contrast.

Answer: (B)

The main idea is that MRI is the best next step for characterizing a liver lesion that remains indeterminate on CT because it provides far superior tissue contrast and a range of sequences that reveal both anatomy and biology of the lesion. Using liver-specific contrast agents, MRI can show how a lesion takes up hepatocytes in the hepatobiliary phase, which helps distinguish lesions like FNH (usually shows hepatocyte uptake) from adenoma or malignant nodules (which may not uptake). Dynamic contrast-enhanced imaging reveals characteristic enhancement patterns—hemangiomas have peripheral nodular enhancement with progressive fill-in, FNH often enhances strongly in the arterial phase with benign appearance on later phases, adenomas can show arterial hyperenhancement with variable washout, hepatocellular carcinoma tends to be arterially hyperenhancing with washout, and many metastases show restricted diffusion with rim or nodular enhancement. Diffusion-weighted imaging adds another layer by assessing cellularity, aiding separation of benign from malignant lesions. In short, MRI provides the most definitive characterization, whereas ultrasound or CT without contrast does not offer the same detail, and PET-CT has limited specificity for liver lesion characterization.

The main idea is that MRI is the best next step for characterizing a liver lesion that remains indeterminate on CT because it provides far superior tissue contrast and a range of sequences that reveal both anatomy and biology of the lesion. Using liver-specific contrast agents, MRI can show how a lesion takes up hepatocytes in the hepatobiliary phase, which helps distinguish lesions like FNH (usually shows hepatocyte uptake) from adenoma or malignant nodules (which may not uptake). Dynamic contrast-enhanced imaging reveals characteristic enhancement patterns—hemangiomas have peripheral nodular enhancement with progressive fill-in, FNH often enhances strongly in the arterial phase with benign appearance on later phases, adenomas can show arterial hyperenhancement with variable washout, hepatocellular carcinoma tends to be arterially hyperenhancing with washout, and many metastases show restricted diffusion with rim or nodular enhancement. Diffusion-weighted imaging adds another layer by assessing cellularity, aiding separation of benign from malignant lesions. In short, MRI provides the most definitive characterization, whereas ultrasound or CT without contrast does not offer the same detail, and PET-CT has limited specificity for liver lesion characterization.